Relmada Therapeutics (RLMD) Income from Non-Controlling Interests (2021 - 2022)
Relmada Therapeutics (RLMD) reported Income from Non-Controlling Interests of -$39.7 million for Q1 2022, down 78.91% year-over-year from -$188.5 million in Q1 2021, and down 78.91% on a QoQ basis from -$22.2 million in Q1 2021.
Relmada Therapeutics (RLMD) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$39.7 million in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -39.75 Mn |
| Mar 31, 2021 | -22.22 Mn |